CureVac NV (WBO:CVAC) Interest Expense : €-2.5 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CureVac NV's interest expense for the three months ended in Sep. 2024 was € -0.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was €-2.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CureVac NV's Operating Income for the three months ended in Sep. 2024 was € 367.4 Mil. CureVac NV's Interest Expense for the three months ended in Sep. 2024 was € -0.1 Mil. CureVac NV's Interest Coverage for the quarter that ended in Sep. 2024 was 2,605.75. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CureVac NV Interest Expense Historical Data

The historical data trend for CureVac NV's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Interest Expense Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.46

-22.10

-10.34

-3.71

-2.49

CureVac NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.60	-1.82	-0.34	-0.16	-0.14

CureVac NV Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.5 Mil.

CureVac NV (WBO:CVAC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CureVac NV's Interest Expense for the three months ended in Sep. 2024 was €-0.1 Mil. Its Operating Income for the three months ended in Sep. 2024 was €367.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was €34.9 Mil.

CureVac NV's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2024 )	/	Interest Expense (Q: Sep. 2024 )
	=	-1	*	367.411	/	-0.141
	=	2,605.75

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. CureVac NV has enough cash to cover all of its debt. Its financial situation is stable.

CureVac NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CVAC:USA 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.